Revelation Biosciences (REVB) Change in Cash (2020 - 2025)
Revelation Biosciences (REVB) posted quarterly Change in Cash of -$2.0 million for Q4 2025, down 4677.46% year-over-year from $43870.6 in Q4 2024, and down 126.65% quarter-over-quarter from $7.5 million in Q3 2025.
Revelation Biosciences (REVB) Change in Cash (2020 - 2025) Analysis & Trends
Revelation Biosciences (REVB) has reported Change in Cash for 6 consecutive years, with -$2.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Cash fell 4677.46% year-over-year to -$2.0 million; the TTM figure through Dec 2025 stood at $4.2 million (up 176.49% YoY), while the FY2025 annual figure was $4.2 million, up 176.49% from the prior year.
- Change in Cash slipped to -$2.0 million in Q4 2025 per REVB's latest filing, from $7.5 million in the prior quarter.
- Across five years, Change in Cash topped out at $12.4 million in Q1 2023 and bottomed at -$5.5 million in Q3 2024.
- Historically, Change in Cash has averaged $310396.6 across 5 years, with a median of -$1.9 million in 2023.
- On a YoY basis, Change in Cash climbed as much as 236.2% in 2025 and fell as far as 4677.46% in 2025.
- Revelation Biosciences' Change in Cash stood at -$2.9 million in 2021, then surged by 67.08% to -$942467.0 in 2022, then tumbled by 112.51% to -$2.0 million in 2023, then soared by 97.9% to -$42034.0 in 2024, then plunged by 4677.46% to -$2.0 million in 2025.
- Business Quant data shows REVB's Change in Cash at -$2.0 million in Q4 2025, $7.5 million in Q3 2025, and $1.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.01 Mn |
| Sep 30, 2025 | 7.53 Mn |
| Jun 30, 2025 | 1.47 Mn |
| Mar 31, 2025 | -2.79 Mn |
| Dec 31, 2024 | -42,034.00 |
| Sep 30, 2024 | -5.53 Mn |
| Jun 30, 2024 | -2.48 Mn |
| Mar 31, 2024 | 2.56 Mn |
| Dec 31, 2023 | -2.00 Mn |
| Sep 30, 2023 | -1.72 Mn |
| Jun 30, 2023 | -1.99 Mn |
| Mar 31, 2023 | 12.45 Mn |
| Dec 31, 2022 | -942,467.00 |
| Sep 30, 2022 | 2.72 Mn |
| Jun 30, 2022 | -3.71 Mn |
| Mar 31, 2022 | 5.91 Mn |
| Dec 31, 2021 | -2.86 Mn |
| Sep 30, 2021 | -2.23 Mn |
| Jun 30, 2021 | -3.64 Mn |
| Mar 31, 2021 | 5.52 Mn |